News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

GBI Research Release: Pharma Research Companies Dragged into the Technological Age, as eClinical Trial Solutions Dominate

7/19/2012 9:44:25 AM

NEW YORK (GBI Research), 19 June 2012 - The global economic recession has led to many pharma companies cutting their spending, but investments in technology could help to improve the efficiency of clinical trials, states a new report by healthcare experts GBI

The new report* shows that eClinical trial solutions can increase the annual savings made by a medical research facility, as automated data processing improves functionality, security, compliance and costs within clinical trials. Pharmaceutical companies are continually looking for better ways to reduce the time from the end-of-study to FDA submission. Delays in collecting, verifying and auditing the accuracy of data, and converting that data into the right format for statistical analysis, must therefore be addressed. As pharmaceutical companies and Clinical Research Organizations (CROs) manage increasing amounts of clinical information, ensuring data integrity and complying with industry standards becomes more important than ever, and minimizing the time between conducting a trial and producing finalized data set is crucial in speeding up the process of getting drugs to the FDA and the market.

GBI Research finds that eClinical trial solutions are widely adopted by pharmaceutical companies and CROs around the world due to the many advantages offered by the technology. Clinical Data Management Systems (CDMS), Electronic Data Capture (EDC), Clinical Trial Management Systems (CTMS), Electronic Patient Reported Outcomes (ePROs), Radio Frequency Identification Tags (RFIDs) and eDiaries all embody eClinical trial solutions, and the market is witnessing increasing innovation.

The growing complexity of clinical trials and an increased focus on accuracy and costs have brought several eClinical technologies into the market, as companies allocate special budgets to increase their annual savings.

EDC is the most commonly used method for capturing data electronically in clinical trials, replacing paper-based methods. EDC is set to witness huge growth in the next five years, and vendors are ready to take on complex issues in order to meet industry expectations.

However, a high dependence on traditional methods of capturing clinical trial data still holds some pharma companies from investing in eClinical trial solutions. Even with the phenomenal rise in demand, many companies are reluctant to embrace the technological age, for fear of problems caused by initial models. However, currently marketed products are less complex and more user friendly. In the long term future companies must adapt to eClinical technologies, else the overwhelming data volumes that clinical trials provide will cause various issues like loss of data, delays in approval processes and decline in overall Return on Investment (ROI).

*e-Clinical Trial Solutions Market to 2018 - Growing Complexity of Clinical Trials and Increased Focus on Accuracy and Efficiency Drive Trial Sponsors to Adopt Novel Technologies

The report provides key data and analysis of the major factors affecting the market for eClinical trial solutions in the pharmaceuticals industry. It also analyzes the opportunities and threats in the eClinical trial solutions market, and the key market drivers and barriers to the adoption of eClinical trial solutions in the industry.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.


GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.

For more information, please contact our Press Office on +44 (0)1204 543 537 or at

Read at

comments powered by Disqus